Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Contribution of secretory leukocyte proteinase inhibitor to the antiprotease defense system of the peripheral lung: effect of ozone-induced acute inflammation.

Authors: Nadziejko, C; Finkelstein, I; Balmes, J R

Published In Am J Respir Crit Care Med, (1995 Nov)

Abstract: Secretory leukocyte protease inhibitor (SLPI) and elafin are structurally similar, low-molecular-weight antiproteases produced in the lung. We have developed a simple method for distinguishing the antiprotease activities of SLPI and elafin in lung lavage fluid from those of alpha 1-antitrypsin (alpha 1-AT) that is based on the resistance of the low-molecular-weight antiproteases to inactivation by cetyltrimethylammonium bromide. In a study of 23 healthy, nonsmoking volunteers, we found that the low-molecular-weight antiproteases accounted for 22 +/- 2% (mean +/- SEM, n = 23) of the total neutrophil elastase-inhibitory capacity of human bronchoalveolar lavage fluid (BALF). Elafin activity was below the limit of detection. SLPI activity (as measured by inhibition of alpha-chymotrypsin) accounted for 72 +/- 4% (mean +/- SEM, n = 23) of the low-molecular-weight antiprotease activity in BALF. Measurements of SLPI in the lavage fluid samples by enzyme-linked immunosorbent assay (ELISA) agreed closely with values obtained by measuring the activity of this inhibitor. The activity of the low-molecular-weight antiproteases decreased significantly (p < 0.05), from 9.0 +/- 0.8 to 7.0 +/- 0.6 pmol of neutrophil elastase inhibited per mL (mean +/- SEM, n = 23), following acute ozone exposure.

PubMed ID: 7582300 Exiting the NIEHS site

MeSH Terms: Acute Disease; Adult; Bronchoalveolar Lavage Fluid/chemistry; Bronchoscopy; Cross-Over Studies; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lung/drug effects; Lung/enzymology*; Male; Molecular Weight; Ozone/adverse effects*; Pneumonia/chemically induced; Pneumonia/enzymology*; Proteins/analysis; Proteins/physiology*; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Serine Proteinase Inhibitors/analysis; Serine Proteinase Inhibitors/physiology*; Single-Blind Method

Back
to Top